2025-02-06 IDOPRESS

Award Recognizes Companies Who Achieve Highest Level of Safety
BEVERLY,Mass.,Feb. 3,2025 --Axcelis Technologies,Inc. (Nasdaq: ACLS),a leading supplier of enabling ion implantation solutions for the semiconductor industry,has received the '2024 SK hynix CSO Safety and Health Award'. This prestigious award honors companies whose dedication and commitment in supplying products and services meet SK hynix's high standards for fab site and personal safety. The award was presented by Kim Youngsik,Chief Production Officer (CPO) of SK hynix,at a ceremony held at the SK hynix SUPEX Center in Icheon,Korea. Recipients are a select group of suppliers chosen for their exemplary performance in the areas of: Compliance with Regulations,Compliance with SK hynix policies,Improvements in the Company's EHS performance,and Reducing Overall Risks in the Semiconductor Supply Chain.
"It is an honor for Axcelis to receive the 2024 SK hynix CSO Safety and Health Award from SK hynix," said Russell Low,Axcelis' President and Chief Executive Officer. "This award is a testament to our dedication to customer collaboration and satisfaction,and our unwavering commitment to environmental sustainability and health and safety.
Vice President Kim Youngsik,commented,"Axcelis' exceptional commitment to health and safety has set them apart and is foundational to helping us achieve our priorities and serve our customers."
About Axcelis:
Axcelis (Nasdaq: ACLS),headquartered in Beverly,has been providing innovative,high-productivity solutions for the semiconductor industry for over 45 years. Axcelis is dedicated to developing enabling process applications through the design,manufacture and complete life cycle support of ion implantation systems,one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.
CONTACTS:
Press/Media Relations Contact:
Maureen Hart
Senior Director,Corporate & Marketing Communications
Telephone: (978) 787-4266
Email: Maureen.Hart@axcelis.com
Axcelis Investor Relations Contact:
David Ryzhik
Senior Vice President,Investor Relations and Corporate Strategy
Telephone: (978) 787-2352
Email: David.Ryzhik@axcelis.com
Logo - /up/2025/0206/25020620014394205659.jpg
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
©copyright 2009-2020 Singapore Info Map